NasdaqGM - Nasdaq Real Time Price USD

Atai Life Sciences N.V. (ATAI)

1.9100

-0.0700

(-3.54%)

At close: April 18 at 4:00 PM EDT

1.9200

+0.01

(+0.52%)

After hours: April 18 at 7:41 PM EDT

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally.BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with single doses of up to 12 mg in healthy participants.Subjective psychedelic effects correlated with 5-MeO-DMT exposure and had a rapid onset and short duration, with acute effects resolving in less than two hours. NEW YOR

GlobeNewswire yesterday

ATAI
-3.54%
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2023 Results Key Financial Results Net loss: US$40.2m (loss narrowed by...

Simply Wall St. 17 days ago

ATAI
-3.54%
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) Phase 1b study, with optimized

GlobeNewswire 21 days ago

ATAI
-3.54%
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12 - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 12 - BPL-003 showed a good safety profile and was well-tolerated with no serious adverse events reported - Acute effects resolved on average in less than two hours, highlighting BPL-003’s potential to fit within the

GlobeNewswire 22 days ago

ATAI
-3.54%
atai Life Sciences advances VLS-01 for treatment-resistant depression

atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion.

News Direct last month

ATAI
-3.54%
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed as a rapid-acting and durable antidepressant for treatment resistant depression, which affects approximately 100 million people globallyVLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradig

GlobeNewswire last month

ATAI
-3.54%
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024. A live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events. A replay of the webcast will

GlobeNewswire last month

ATAI
-3.54%
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company’s CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. “Anne has been an integral member of our team for

GlobeNewswire 2 months ago

ATAI
-3.54%
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector This week was the inaugural week of 2024, a year poised to be a dynamic rollercoaster of highs and lows in the ever-evolving landscape of the cannabis and psychedelic sectors. As we step into the unknown, anticipation runs high, especially in the cannabis sector, where investors eagerly […]

Market Exclusive 3 months ago

VFF

AWKNF

TCNNF
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai’s existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatm

GlobeNewswire 3 months ago

ATAI
-3.54%
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and a range of exploratory pharmacodynamic (PD) measures, including subjective reports and blood-based biomarkers, showed dose-dependent changes EMP-01 administration resulted in a differentiated subjective experience compared to racemic MDMA, a result that is likely to have therapeutic implications NEW YORK and BERLIN, Jan. 02, 2024 (GLOBE NEWSW

GlobeNewswire 3 months ago

ATAI
-3.54%
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove

GlobeNewswire 5 months ago

ATAI
-3.54%
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

This press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023.

CNW Group 6 months ago

ATAI
-3.54%
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at 8:30 A.M. ET Location: New

GlobeNewswire 6 months ago

ATAI
-3.54%
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comparable to those achieved with IV administrationCompany plans to further optimize VLS-01 in preparation for a Phase 2 study in treatment-resistant depression (TRD) NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“at

GlobeNewswire 6 months ago

ATAI
-3.54%
Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV

On September 13, 2023, Florian Brand, See Remarks at ATAI Life Sciences NV (NASDAQ:ATAI), made a significant purchase of 40,000 shares of the company's stock.

GuruFocus.com 7 months ago

ATAI
-3.54%
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company’s participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET Location: New York, NY A webcast o

GlobeNewswire 7 months ago

ATAI
-3.54%
atai Life Sciences to Participate in Upcoming September Investor Conferences

NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences. Details of the company’s participation are as follows: Citi's 18th Annual BioPharma Conference Format: 1x1 Only Date: Thursday, September 7th Location: Boston, MA H.C. Wainwright 25th Annual Global Investment Conference Format: Firesi

GlobeNewswire 7 months ago

ATAI
-3.54%
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with SchizophreniaDMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use DisorderThe Company’s $227M cash position and committed term loan funding is expected to fund operations into 1H 2026 NEW YORK and BERLIN, Aug. 10, 2023 (GLOBE NEWSWIRE

GlobeNewswire 8 months ago

ATAI
-3.54%
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine). The Phase 1 open-label, 4-period crossover study assessed the safety, tolerability, and pharmacokinetic profile of 60mg, 90mg and 120mg of PCN-101 delivered subcutaneously

GlobeNewswire 8 months ago

ATAI
-3.54%

Performance Overview

Return	ATAI	S&P 500
YTD	+35.46%	+5.06%
1-Year	-2.05%	+20.71%
3-Year	--	+20.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Atai Life Sciences N.V. (ATAI)

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences advances VLS-01 for treatment-resistant depression

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights

ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORT

atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit

atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NV

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

atai Life Sciences to Participate in Upcoming September Investor Conferences

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Performance Overview